EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

TAAR1 agonist ulotaront delays gastric emptying of solids in patients with schizophrenia and concurrent metabolic syndrome with prediabetes

Snežana Milanović, Nina Dedic iD, Robert Lew, Duane Burton, Kenneth S Koblan, Michael Camilleri iD, Seth C Hopkins iD

Diabetes, Obesity and Metabolism · 2024

DOI: 10.1111/dom.15569 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Diabetes, Obesity and Metabolism, 2024. Verfasst von Snežana Milanović und 6 weiteren Autor:innen. Beteiligte Einrichtung: Sumitomo Pharma America, Inc., Marlborough, Massachusetts, USA. Hauptthemen laut MEDLINE: Gastric Emptying, Schizophrenia, Metabolic Syndrome, Prediabetic State. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Metabolic syndrome (MetS), which can be induced or exacerbated by the current class of antipsychotic drugs, is highly prevalent in patients with schizophrenia and presents significant challenges to lifetime disease management. Supported by initial clinical results, trace amine‐associated receptor 1 (TAAR1) agonists have emerged as potential novel treatments for schizophrenia. Notably, non‐clinical studies have also shown weight‐lowering and glucoregulatory effects of TAAR1 agonists, including the investigational agent ulotaront. However, the translatability of these findings to humans has not been adequately assessed. Given that delayed gastric emptying (GE) was identified as a potential mechanism contributing to the metabolic benefits of TAAR1 agonists in rodents, the aim of this study was to evaluate the effect of ulotaront on GE in patients with schizophrenia and concurrent MetS with prediabetes.

Methods

Patients with schizophrenia were randomized to receive a single oral dose of ulotaront (150 mg) and their previous antipsychotic (PA) in an open‐label, crossover, two‐sequence design (NCT05402111). Eligible participants fulfilled at least three of five MetS criteria and had prediabetes defined by elevated glycated haemoglobin (5.7‐6.4%) and/or fasting homeostatic model assessment of insulin resistance (i.e. ≥2.22). Following an overnight fast and 4 h post‐dose, participants ingested a 99m Tc‐sulphur colloid radiolabelled egg meal (320 kcal, 30% fat). GE was measured by scintigraphy over 4 h. Endpoints included GE of solids half‐time (T 1/2 ) and percentage gastric retention at 1, 2 and 4 h.

Results

Thirty‐one adults were randomized and 27 completed the study. Ulotaront significantly delayed GE of solids [median GE T 1/2 ulotaront at 139 min (119, 182) vs. the participant's PA of 124 min (109, 132), p = .006]. A significant increase in gastric retention was seen in the ulotaront versus the PA group at 1 h (80% vs. 75%, p = .015), 2 h (61% vs. 50%, p = .023) and 4 h (17% vs. 7%, p = .002) post‐meal.

Conclusion

Ulotaront delayed the GE of solids in patients with schizophrenia and concurrent MetS with prediabetes. Additional studies are needed to assess whether treatment with TAAR1 agonists is associated with weight loss and glucoregulatory improvement.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gastric EmptyingSchizophreniaMetabolic SyndromePrediabetic StateAntipsychotic AgentsReceptors, G-Protein-CoupledCross-Over StudiesHumansMaleFemaleAdultMiddle AgedTetrahydronaphthalenesNaltrexoneTrace Amine-Associated Receptors

Stichwörter der Autor:innen

appetite controlclinical trialdrug developmentdrug mechanism

Substanzen

Antipsychotic AgentsReceptors, G-Protein-CoupledTetrahydronaphthalenesNaltrexoneTrace Amine-Associated Receptors3-carboxamido-4-hydroxynaltrexone

Autor:innen und Institutionen

  • Sumitomo Pharma America, Inc., Marlborough, Massachusetts, USA.
  • Mayo Clinic, Rochester, Minnesota, USA.

ORCID-Profile: Nina Dedic, Michael Camilleri, Seth C Hopkins

Zitieren

APA

Milanović, S., Dedic, N., Lew, R., Burton, D., Koblan, K. S., Camilleri, M., & Hopkins, S. C. (2024). TAAR1 agonist ulotaront delays gastric emptying of solids in patients with schizophrenia and concurrent metabolic syndrome with prediabetes. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.15569

Vancouver

Milanović S, Dedic N, Lew R, Burton D, Koblan KS, Camilleri M, et al. TAAR1 agonist ulotaront delays gastric emptying of solids in patients with schizophrenia and concurrent metabolic syndrome with prediabetes. Diabetes, Obesity and Metabolism. 2024. doi:10.1111/dom.15569

BibTeX
@article{Milanovi2024,
  author = {Milanović, Snežana and Dedic, Nina and Lew, Robert and Burton, Duane and Koblan, Kenneth S and Camilleri, Michael and Hopkins, Seth C},
  title = {TAAR1 agonist ulotaront delays gastric emptying of solids in patients with schizophrenia and concurrent metabolic syndrome with prediabetes},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2024},
  doi = {10.1111/dom.15569}
}
Kostenlos starten →